Albany Molecular Research Inc. (AMRI)
Symbol Info
Listed Symbol AMRI
Name Albany Molecular Research Inc.
Share Info
Annual Info
Latest Fiscal Dividend Per Share $-
Latest Fiscal Date 2016-12-31
Latest Fiscal Revenue $570,449,000
Latest Fiscal EPS $-1.82
Price Info
21 Day Moving Average $21.7305
21 Day EMA $21.717650
50 Day Moving Average $21.7104
50 Day EMA $21.310260
200 Day EMA $18.828180
200 Day Moving Average 18.263250
52 Week High $22.17
52 Week Low $13.01
52 Week Change $46.693700
Alpha 0.029298
Beta 1.1450
Standard Deviation 0.137693
R2 0.052350
Periods 60
Share Information
10 Day Average Volume 1,068,321
20 Day Average Volume 749,013
30 Day Average Volume 747,012
50 Day Average Volume 790,982
Outstanding Shares 43,119,283
Float Shares 36,473,298
Percent Float 84.59%
Short Interest -
Short Percent Float -
Short Interest Ratio -
Short Date
Holders
Institutions 202
Institute Holdings Date 2017-06-30
Institute Bought Previous 3 Months 2,700,933
Institute Holdings Percent 89.500000
Institute Sold Previous 3 Months 2,334,097
Insider Holdings Date
Insider Bought Previous 3 Months -
Insider Holdings Percent -
Insider Sold Previous 3 Months -
Insiders Shares Owned 6,645,985
Price Change
7 Day Price Change $0.0200005
7 Day Percent Change 0.09%
21 Day Price Change $-0.0100002
21 Day Percent Change -0.05%
30 Day Price Change $-
30 Day Percent Change -
Month To Date Price Change $-
Month To Date Percent -
90 Day Price Change $2.280001
90 Day Percent Change 11.72%
Quarter To Date $0.039999
Quarter To Date Percent 0.18%
180 Day Price Change $6.770000
180 Day Percent Change 45.22%
200 Day Price Change $3.080000
200 Day Percent Change 16.51%
Year To Date $2.980000
Year To Date Percent 15.88%
Profile
Description Albany Molecular Research provides research services to pharmaceutical, biotechnology, and chemical companies. The company offers services like design and modification of potential lead compounds, purification technique development, quality control, bulk ingredient stability studies, and regulatory documentation preparation. The company has entered into collaborative agreements with companies like Eli Lilly and Cambrex. Albany's acquisition of Organichem provided the company with commercial manufacturing capabilities.
Details
Issue Type CS
Market Cap $937,413,212
Sec Type EQS
Auditor KPMG LLP
Total Shares Outstanding -
CEO William S. Marth
Employees 3,085
Last Audit UQ
Classification
CIK 0001065087
Industry Biotechnology
Sector Healthcare
NAICS Research and Development in Biotechnology (except Nanobiotechnology)(541714)
Info
Address 26 Corporate Circle
Albany, NY 12212
Website http://www.amriglobal.com
Facisimile +1 518 512-2020
Telephone +1 518 512-2000
Email Peter.jerome@amriglobal.com
Key Ratios
Profitability
EBIT Margin -3
EBITDA Margin 7.0
Pre-Tax Profit Margin -1.1
Profit Margin Cont -9.28
Gross Margin 22.10
Profit Margin TOT -9.28
Income Statements
Revenue $680,814,000
Revenue Per Share $15.7891
Revenue 3 Years $32.85
Revenue 5 Years $24.53
Valuation Measures
PE Ratio -
Enterprise Value $1,543,149,212
Price To Sales 1.376901
Price To Free Cash -5.9
PE High Last 5 Years -
Price To Book 3.0
Price To Cash Flow 46.0
PE Low Last 5 Years -
Price To Tangible Book -10.4
Financial Strength
Total Debt To Equity 2.0
Int Coverage -4.2
Current Ratio 0.7
Leverage Ratio 3.9
Quick Ratio 0.3
Long Term Debt To Capital 0.38
Assets
Receivables Turnover 5.2
Invoice Turnover 3.80
Assets Turnover 0.70
Management Effectiveness
Return Assets -5.77
Return On Equity -20.35
Return On Capital -7.42
Dividends
Dividend 3 Years $-
Dividend 5 Years $-
Ex Dividend Date
Dividend Rate $-
Dividend Yield -
Payment Type


Your Recent History
NASDAQ
AMRI
Albany Mol..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.


NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.